tbuckley/cabot-search huggingface dataset:
TCT-150 New Multiple Risk Scoring System for Predicting 3-Year Major Adverse Cardiac Events Based on 3,281 Patients With Acute Myocardial Infarction Treated With Contemporary PCI and Optimal Medical Therapy: Insights from J-MINUET Study
Authors: Yukio Ozaki, Yu Yoshiki, Koichi Nakao, Kazuo Kimura, Junya Ako, Teruo Noguchi, Satoru Suwa, Kazuteru Fujimoto, Kazuoki Dai, Takashi Morita, Hidemaro Takatsu, Yousuke Hashimoto, Masakazu Kobayashi, Takashi Muramatsu, Hideo Izawa, Hiroshi Takahashi, Kunihiro Nishimura, Masaharu Ishihara
Journal: Journal of the American College of Cardiology (2021)
Abstract 12763: Impact of Baseline Thrombocytopenia on Mortality and Recurrent Heart Failure in Patients With Acute Heart Failure
Authors: Shinya Ito, Kyohei Yamaji, Miho Nakamura, Shinpei Fujioka, Kaoru Hirose, Shintaro mori, Mariko Yano, Takashi Morinaga, Akihiro Isotani, Makoto Hyodo, Shinichi Shirai, Kenji Ando
Journal: Circulation (2018)

Introduction: Thrombocytopenia was reported to be a prognostic indicator in patients with reduced ejection fraction, but it remained unclear whether thrombocytopenia is associated with adverse clin...
A Src-H3 acetylation signaling axis integrates macrophage mechanosensation with inflammatory response
Authors: Praveen Krishna Veerasubramanian, Hanjuan Shao, Vijaykumar S. Meli, Tri Andrew Q. Phan, Thuy U. Luu, Wendy F. Liu, Timothy L. Downing
Journal: Biomaterials (2021)

Macrophages are mechanosensitive cells that can exquisitely fine-tune their function in response to their microenvironment. While macrophage polarization results in concomitant changes in cell morphology and epigenetic reprogramming, how biophysically-induced signaling cascades contribute to gene regulatory programs that drive polarization remains unknown. We reveal a cytoskeleton-dependent Src-H3 acetylation (H3Ac) axis responsible for inflammation-associated histone hyperacetylation. Inflammatory stimuli caused increases in traction forces, Src activity and H3Ac marks in macrophages, accompanied by reduced cell elongation and motility. These effects were curtailed following disruption of H3Ac-signaling through either micropattern-induced cell elongation or inhibition of H3Ac readers (BRD proteins) directly. Src activation relieves the suppression of p300 histone acetyltransferase (HAT) activity by PKCδ. Furthermore, while inhibition of Src reduced p300 HAT activity and H3Ac marks globally, local H3Ac levels within the Src promoter were increased, suggesting H3Ac regulates Src levels through feedback. Together, our study reveals an adhesome-to-epigenome regulatory nexus underlying macrophage mechanosensation, where Src modulates H3Ac-associated epigenetic signaling as a means of tuning inflammatory gene activity and macrophage fate decisions in response to microenvironmental cues.
Discussing Do-Not-Resuscitate Status: Furthering the Discourse
Authors: Michael Naughton, Mellar Davis, Charles F. von Gunten
Journal: Journal of Clinical Oncology (2001)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.13.3301 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11432904 Discussing Do-Not-Resuscitate Status: Furthering the Discourse Michael NaughtonxMichael NaughtonSearch for articles by this author , Mellar DavisxMellar DavisSearch for articles by this author Charles F. von GuntenxCharles F. von GuntenSearch for articles by this author Show More Cleveland Clinic Foundation, Cleveland, OHCenter for Palliative Studies, San Diego, CA https://doi.org/10.1200/JCO.2001.19.13.3301 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01072001In Reply:Drs Naughton and Davis have written approvingly about the overall approach to discussing do-not-resuscitate (DNR) status that I presented.1 They accurately describe some of the additional complexities that may arise in the care of some patients.My goal in writing the article was to describe a basic structure for the clinical conversation about DNR status. I intended it for beginners or those who feel in need of help with the common challenges encountered in practice. Too many clinicians know all about DNR but have no practical guidance to develop the necessary clinical skills. I was anxious not to obscure the usual and ordinary with the unusual and extraordinary. Neither did I want to present so many exceptions and complications that the novice would feel discouraged.Consequently, I appreciate the discussion of complexities and exceptions presented by these thoughtful expert clinicians. As for so many aspects of oncology, complexities and exceptions require additional knowledge and expertise. Naughton and Davis describe excellent insights for clinicians who have mastered the basics.REFERENCE1. von Gunten CF: Discussing do-not-resuscitate status. J Clin Oncol 19:: 1576,2001-1581, Link, Google Scholar
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
Authors: Ling‐Long Tang, Yu‐Pei Chen, Chuan‐Ben Chen, Ming‐Yuan Chen, Nian‐Yong Chen, Xiao‐Zhong Chen, Xiao‐Jing Du, Wen‐Feng Fang, Mei Feng, Jin Gao, Fei Han, Xia He, Chao‐Su Hu, De‐sheng Hu, Guang‐Yuan Hu, Hao Jiang, Wei Jiang, Feng Jin, Jin‐Yi Lang, Jin‐Gao Li, Shao‐Jun Lin, Xu Liu, Qiu‐Fang Liu, Lin Ma, Hai‐Qiang Mai, Ji‐Yong Qin, Liang‐Fang Shen, Ying Sun, Pei‐Guo Wang, Ren‐Sheng Wang, Ruo‐Zheng Wang, Xiao‐Shen Wang, Ying Wang, Hui Wu, Yun‐Fei Xia, Shao‐Wen Xiao, Kun‐Yu Yang, Jun‐Lin Yi, Xiao‐Dong Zhu, Jun Ma
Journal: Cancer Communications (2021)

Abstract Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi‐disciplinary team comprising of experts from all sub‐specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence‐based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow‐up of NPC, which aim to improve the management of NPC.
Considerations for Optimal Administration of Chimeric Antigen Receptor (CAR) T-Cell Therapy Programs: A Multi-Stakeholder Qualitative Analysis
Authors: Daanish Hoda, Edward Faber, Bradley Hunter, Abhinav Deol, Concetta Crivera, Carrie Riccobono, Ashraf Garrett, Carolyn C. Jackson, Jessica Fowler, Ariel Berger, Andrea L Lorden, Raj Stewart
Journal: Blood (2021)
Heterogeneous origin of IgE in atopic dermatitis and psoriasis revealed by B cell receptor repertoire analysis
Authors: Lihua Luo, Yang Luo, Jing Xu, Ronghui Zhu, Jinghua Wu, Xiao Liu, Wei Li, Xu Yao
Journal: Allergy (2021)

Epicutaneous sensitization is an important route for the production of IgE, and skin inflammation-induced IgE has recently been reported having features of natural antibody. Atopic dermatitis (AD) and psoriasis have differentially increased level of serum IgE; however, the production mechanism of IgE in these inflammatory skin diseases remains unknown.To explore the origin of IgE in AD and psoriasis by analyzing the B cell receptor repertoire.mRNA was prepared from peripheral blood mononuclear cells of AD and psoriasis patients that had elevated serum levels of IgE, and immunoglobulin heavy chain (IGH) repertoires were sequenced after reverse transcription. Clonal lineages of B cells containing members expressing IgE were identified, and somatic hypermutations in IGH inherited from common ancestors within the clonal lineage were used to infer the relationships between B cells.The proportions of IGHE from AD and psoriasis were higher than that of normal control, which were positively correlated with the levels of serum total IgE. The somatic hypermutation value of IGHE variable region was lower than that of IGHG and IGHA, but higher than IGHM and IGHD, indicating a mixed natural and adaptive origins of IgE; and psoriasis demonstrated lower level of hypermutation than AD. The Shannon indexes of CDR3 in IGHE of AD and psoriasis were higher than that of normal control, also supporting the natural origin. The VH usage of IgE was weakly biased in AD and psoriasis patients with high level of house dust mite-specific IgE. Comparison of the number of shared mutations in multi-isotype lineages containing IgE showed that isotype-switching from IgG-expressing B cells might be the major source of IgE in AD and psoriasis.IgE has heterogeneous origin in AD and psoriasis, and skin inflammation may contribute to the increased production of natural IgE.
TCT-355 Permanent Pacemaker Implantation Rate After Transcatheter Aortic Valve Replacement With Self-Expandable Device and Their Relationship With Cusp-Overlap Technique
Authors: Luis Perez, Reinaldo Venegas, Guillermo Ibieta, Felipe Sepulveda, Eduardo Lecannelier, Jatun Saez, Alicex Gonzalez, Gianpaolo Cecioni, Eugenio Sanhueza, Constanza Sandoval, Virginia Segall, Isabel Lorena Robles Paredes, Maricela Proboste
Journal: Journal of the American College of Cardiology (2021)
Особенности абдоминального болевого синдрома у пациентов с функциональными и воспалительными заболеваниями кишечника и методы его коррекции
Authors: A.E. Dorofeiev, O.A. Rassokhina, Ye.А. Кirian, I.А. Derkach, А.Yu. Butova
Journal: GASTROENTEROLOGY (2014)

Целью данного исследования было изучение особенностей абдоминального болевого синдрома у пациентов с синдромом раздраженного кишечника (СРК) и воспалительными заболеваниями кишечника (ВЗК) и оценка эффективности применения Энтероспазмила в комплексе терапии этих больных. Было обследовано 120 пациентов с СРК и 35 больных ВЗК. Возраст пациентов варьировал от 18 до 65 лет. Абдоминальный болевой синдром наблюдался у всех больных с СРК и ВЗК. У обследованных отмечались преимущественно вариабельные боли, без иррадиации, чаще тупого, ноющего характера, длительностью более 3 часов, средней интенсивности. Энтероспазмил является эффективным препаратом для купирования абдоминальной боли у больных с СРК и ВЗК и может быть использован в комплексе терапии этих пациентов.
Abstract 1589: Pulmonary Hypertension Is Associated With Regional Right Ventricular Systolic Dysfunction And Dyssynchrony: Strain and Strain Rate Assessment Using Velocity Vector Imaging Technique.
Authors: Hong Meng, Hector R Villarraga, PuWai Lee, Shah A Aijaz, Maytinee Kittipovanonth, James B Seward, Krishnaswamy Chandrasekaran
Journal: Circulation (2007)

Background: Strain and strain rate has been shown to identify subtle contraction abnormalities of left ventricle. Objectives: We hypothesized that S and SR derived from velocity vector imaging (VVI) will allow early identification of global and regional RV systolic function in patients with pulmonary hypertension (PHT) compared to conventional echo parameters. Methods: 96 patients, 35 normal RV Systolic Pressure (RVSP &lt; 30 mmHg) and 61 with PHT, {24 mild-moderate (RVSP &gt; 60 mmHg) and 37 severe (RVSP &lt; 60 mmHg)} underwent echo-Doppler assessment of RV. Apical 4 chamber images at end expiration were used for RV lateral wall (LW) and ventricular septal (VS) segment analysis for systolic tangential velocity (Ta V), S and SR. In addition RV end systolic and diastolic area, RV fractional area change (RV FAC), RV performance index (RIMP) and tricuspid annulus systolic excursion were measured. Results: Peak S, systolic SR and Ta V at the basal, mid and apical segments of the RV LW and VS were depressed in patients with PHT compared with controls, Table 1 , P 0.001. Similarly, significant decrease in RIMP was seen in patients with PHT compared to controls, p &lt;0.001. Significant correlation (p&lt;0.001, r &gt;0.6) was noted between the 2D FAC and S, SR. The time to peak systolic S indexed to end diastolic area (EDA) is significantly prolonged, p&lt;0.01 in all segments in patients with PHT indicating dyssynchrony. Conclusion: S and SR allows assesment of Regional RV systolic function otherwise difficult to assess from conventional echo-Doppler technique. PHTN is associated with not only regional RV systolic dysfunction but also with dyssynchrony. Thus, this new tool can offer new insights in the functioning of right ventricular global and regional function. mean±SD of strain
First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study
Authors: Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda
Journal: Blood (2021)
Integration of genetic, transcriptomic, and clinical data provides insight into 16p11.2 and 22q11.2 CNV genes
Authors: Mikhail Vysotskiy, Xue Zhong, Tyne W. Miller-Fleming, Dan Zhou, Nancy J. Cox, Lauren A. Weiss
Journal: Genome Medicine (2021)

Abstract Background Deletions and duplications of the multigenic 16p11.2 and 22q11.2 copy number variant (CNV) regions are associated with brain-related disorders including schizophrenia, intellectual disability, obesity, bipolar disorder, and autism spectrum disorder (ASD). The contribution of individual CNV genes to each of these identified phenotypes is unknown, as well as the contribution of these CNV genes to other potentially subtler health implications for carriers. Hypothesizing that DNA copy number exerts most effects via impacts on RNA expression, we attempted a novel in silico fine-mapping approach in non-CNV carriers using both GWAS and biobank data. Methods We first asked whether gene expression level in any individual gene in the CNV region alters risk for a known CNV-associated behavioral phenotype(s). Using transcriptomic imputation, we performed association testing for CNV genes within large genotyped cohorts for schizophrenia, IQ, BMI, bipolar disorder, and ASD. Second, we used a biobank containing electronic health data to compare the medical phenome of CNV carriers to controls within 700,000 individuals in order to investigate the full spectrum of health effects of the CNVs. Third, we used genotypes for over 48,000 individuals within the biobank to perform phenome-wide association studies between imputed expressions of individual 16p11.2 and 22q11.2 genes and over 1500 health traits. Results Using large genotyped cohorts, we found individual genes within 16p11.2 associated with schizophrenia ( TMEM219 , INO80E , YPEL3 ), BMI ( TMEM219 , SPN , TAOK2 , INO80E ), and IQ ( SPN ), using conditional analysis to identify upregulation of INO80E as the driver of schizophrenia, and downregulation of SPN and INO80E as increasing BMI. We identified both novel and previously observed over-represented traits within the electronic health records of 16p11.2 and 22q11.2 CNV carriers. In the phenome-wide association study, we found seventeen significant gene-trait pairs, including psychosis ( NPIPB11 , SLX1B ) and mood disorders ( SCARF2 ), and overall enrichment of mental traits. Conclusions Our results demonstrate how integration of genetic and clinical data aids in understanding CNV gene function and implicates pleiotropy and multigenicity in CNV biology.
The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
Authors: Sarah Mbaeyi, Sara E. Oliver, Jennifer P. Collins, Monica Godfrey, Neela D. Goswami, Stephen C. Hadler, Jefferson Jones, Heidi Moline, Danielle Moulia, Sujan Reddy, Kristine Schmit, Megan Wallace, Mary Chamberland, Doug Campos-Outcalt, Rebecca L. Morgan, Beth P. Bell, Oliver Brooks, Camille Kotton, H. Keipp Talbot, Grace Lee, Matthew F. Daley, Kathleen Dooling
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Three COVID-19 vaccines are currently approved under a Biologics License Application (BLA) or authorized under an Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) and recommended for primary vaccination by the Advisory Committee on Immunization Practices (ACIP) in the United States: the 2-dose mRNA-based Pfizer-BioNTech/Comirnaty and Moderna COVID-19 vaccines and the single-dose adenovirus vector-based Janssen (Johnson & Johnson) COVID-19 vaccine (1,2) (Box 1). In August 2021, FDA amended the EUAs for the two mRNA COVID-19 vaccines to allow for an additional primary dose in certain immunocompromised recipients of an initial mRNA COVID-19 vaccination series (1). During September-October 2021, FDA amended the EUAs to allow for a COVID-19 vaccine booster dose following a primary mRNA COVID-19 vaccination series in certain recipients aged ≥18 years who are at increased risk for serious complications of COVID-19 or exposure to SARS-CoV-2 (the virus that causes COVID-19), as well as in recipients aged ≥18 years of Janssen COVID-19 vaccine (1) (Table). For the purposes of these recommendations, an additional primary (hereafter additional) dose refers to a dose of vaccine administered to persons who likely did not mount a protective immune response after initial vaccination. A booster dose refers to a dose of vaccine administered to enhance or restore protection by the primary vaccination, which might have waned over time. Health care professionals play a critical role in COVID-19 vaccination efforts, including for primary, additional, and booster vaccination, particularly to protect patients who are at increased risk for severe illness and death.
TCT-141 In-Hospital Characteristics and Outcomes Among Patients Treated With Off-Label Tricuspid Valve Transcatheter Edge-to-Edge Repair: An Analysis From the National In-Patient Sample 2016-2018
Authors: Christian Torres, Gorav Ailawadi, Marissa Donatelle, Matthew Lozier, Karthik Vedantam, Nirat Beohar
Journal: Journal of the American College of Cardiology (2021)
Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial
Authors: G. Bellingan, F. Jacono, J. Bannard-Smith, D. Brealey, N. Meyer, D. Thickett, D. Young, A. Bentley, B. J. McVerry, R. G. Wunderink, K. C. Doerschug, C. Summers, M. Rojas, A. Ting, E. D. Jenkins
Journal: Intensive Care Medicine (2021)

Bone marrow-derived, allogeneic, multipotent adult progenitor cells demonstrated safety and efficacy in preclinical models of acute respiratory distress syndrome (ARDS). This phase 1/2 trial evaluated the safety and tolerability of intravenous multipotent adult progenitor cells in patients with moderate-to-severe ARDS in 12 UK and USA centres. Cohorts 1 and 2 were open-label, evaluating acute safety in three subjects receiving 300 or 900 million cells, respectively. Cohort 3 was a randomised, double-blind, placebo-controlled parallel trial infusing 900 million cells (n = 20) or placebo (n = 10) within 96 h of ARDS diagnosis. Primary outcomes were safety and tolerability. Secondary endpoints included clinical outcomes, quality of life (QoL) and plasma biomarkers. No allergic or serious adverse reactions were associated with cell therapy in any cohort. At baseline, the cohort 3 cell group had less severe hypoxia. For cohort 3, 28-day mortality was 25% for cell vs. 45% for placebo recipients. Median 28-day free from intensive care unit (ICU) and ventilator-free days in the cell vs. placebo group were 12.5 (IQR 0,18.5) vs. 4.5 (IQR 0,16.8) and 18.5 (IQR 0,22) vs. 6.5 (IQR 0,18.3), respectively. A prospectively defined severe ARDS subpopulation (PaO2/FiO2 < 150 mmHg (20 kPa); n = 16) showed similar trends in mortality, ICU-free days and ventilator-free days favouring cell therapy. Cell recipients showed greater recovery of QoL through Day 365. Multipotent adult progenitor cells were safe and well tolerated in ARDS. The clinical outcomes warrant larger trials to evaluate the therapeutic efficacy and optimal patient population.
Outcomes over the first two years of treatment with mepolizumab in severe asthma
Authors: Lynn Elsey, Thomas Pantin, Leanne-Jo Holmes, Gael Tavernier, Stephen J. Fowler
Journal: European Respiratory Journal (2021)

<b>This study found that 30% of patients stopped mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.</b>https://bit.ly/3ChWN63
TCT-79 Changes in Coronary Lipid Composition During 2-Year Follow-Up After Acute Myocardial Infarction: Serial NIRS-IVUS Assessment From the PROSPECT ABSORB Trial
Authors: Mitsuaki Matsumura, Akiko Maehara, Zhipeng Zhou, Gary Mintz, Ori Ben-Yehuda, Michael Maeng, Lars Kjoller-Hansen, Thomas Engstroem, Ole Fröbert, Jonas Persson, Rune Wiseth, Alf Inge Larsen, Lisette Okkels Jensen, Jan Erik Nordrehaug, Oyvind Bleie, Elmir Omerovic, Claes Held, Stefan James, Ziad Ali, David Erlinge, Gregg Stone
Journal: Journal of the American College of Cardiology (2021)
European Liver Transplant Registry: Donor and transplant surgery aspects of 16,641 liver transplantations in children
Authors: Jean de Ville de Goyet, Ulrich Baumann, Vincent Karam, René Adam, Silvio Nadalin, Nigel Heaton, Raymond Reding, Sophie Branchereau, Darius Mirza, Jürgen L. Klempnauer, Lutz Fischer, Piotr Kalicinski, Michele Colledan, Manuel Lopez Santamaria, Ruben H. de Kleine, Christophe Chardot, Sezai Yilmaz, Murat Kilic, Olivier Boillot, Fabrizio di Francesco, Wojciech G. Polak, Henkjan J. Verkade
Journal: Hepatology (2021)

The European Liver Transplant Registry (ELTR) has collected data on liver transplant procedures performed in Europe since 1968.Over a 50-year period (1968-2017), clinical and laboratory data were collected from 133 transplant centers and analyzed retrospectively (16,641 liver transplants in 14,515 children). Data were analyzed according to three successive periods (A, before 2000; B, 2000-2009; and C, since 2010), studying donor and graft characteristics and graft outcome. The use of living donors steadily increased from A to C (A, n = 296 [7%]; B, n = 1131 [23%]; and C, n = 1985 [39%]; p = 0.0001). Overall, the 5-year graft survival rate has improved from 65% in group A to 75% in group B (p < 0.0001) and to 79% in group C (B versus C, p < 0.0001). Graft half-life was 31 years, overall; it was 41 years for children who survived the first year after transplant. The late annual graft loss rate in teenagers is higher than that in children aged <12 years and similar to that of young adults. No evidence for accelerated graft loss after age 18 years was found.Pediatric liver transplantation has reached a high efficacy as a cure or treatment for severe liver disease in infants and children. Grafts that survived the first year had a half-life similar to standard human half-life. Transplantation before or after puberty may be the pivot-point for lower long-term outcome in children. Further studies are necessary to revisit some old concepts regarding transplant benefit (survival time) for small children, the role of recipient pathophysiology versus graft aging, and risk at transition to adult age.